TY - JOUR T1 - Multidrug-resistant tuberculosis around the world: what progress has been made? JF - European Respiratory Journal JO - Eur Respir J SP - 150 LP - 160 DO - 10.1183/09031936.00101814 VL - 45 IS - 1 AU - Dennis Falzon AU - Fuad Mirzayev AU - Fraser Wares AU - Inés Garcia Baena AU - Matteo Zignol AU - Nguyen Linh AU - Karin Weyer AU - Ernesto Jaramillo AU - Katherine Floyd AU - Mario Raviglione Y1 - 2015/01/01 UR - http://erj.ersjournals.com/content/45/1/150.abstract N2 - Multidrug-resistant tuberculosis (MDR-TB) (resistance to at least isoniazid and rifampicin) will influence the future of global TB control. 88% of estimated MDR-TB cases occur in middle- or high-income countries, and 60% occur in Brazil, China, India, the Russian Federation and South Africa. The World Health Organization collects country data annually to monitor the response to MDR-TB. Notification, treatment enrolment and outcome data were summarised for 30 countries, accounting for >90% of the estimated MDR-TB cases among notified TB cases worldwide. In 2012, a median of 14% (interquartile range 6–50%) of estimated MDR-TB cases were notified in the 30 countries studied. In 15 of the 30 countries, the number of patients treated for MDR-TB in 2012 (71 681) was >50% higher than in 2011. Median treatment success was 53% (interquartile range 40–70%) in the 25 countries reporting data for 30 021 MDR-TB cases who started treatment in 2010. Although progress has been noted in the expansion of MDR-TB care, urgent efforts are required in order to provide wider access to diagnosis and treatment in most countries with the highest burden of MDR-TB. A wider adoption of effective diagnostics, treatment and preventive measures is needed to control MDR-TB globally http://ow.ly/zwZWr ER -